Hepatitis B (HBV) Patient Leuko Pak / Whole Blood / Plasma / Serum
Hepatitis B virus (HBV) infection affects 400 million people worldwide, causing significant shortening of average life expectancy in affected population. The HBV is a circular partially double stranded DNA virus. It is composed of a nucleocapsid core (HBcAg) and surrounded by an outer envelope containing the surface antigen (HBsAg). HBV productively infects hepatocytes and can cause cirrhosis, hepatocellular carcinoma, and liver failure. The entry of HBV into hepatocytes is mediated by the the sodium taurocholate cotransporting polypeptide, a bile acid transporter. Hepatitis B can range from mild to severe. Comparing to acute HBV infection, T cells in chronic infected individuals have been shown to be less responsive to HBV virus, having an exhausted phenotype.
Leuko paks are obtained when they become available to our network of clinicians, by a donation process where blood is withdrawn from the donor via leukapheresis utilizing an apheresis machine such as the COBE Spectra Optia®. The donor’s white blood cells are selectively collected and the remaining blood is reinfused to the body. We can also collect whole blood and plasma samples from the patients. Some disease types may have a long backorder depending on the frequency of the disease occurrence in the general population.
HumanCells’ Hepatitis B products are obtained from patient donors who are fully consented and IRB approved.